Is There a Role for Pharmacoeconomics in Developing Countries?
|
|
- Dominic Warner
- 8 years ago
- Views:
Transcription
1 COMMENTARY Pharmacoeconomics 2010; doi: / /10/ /$49.95/0 ª 2010 Adis Data Information BV. All rights reserved. Is There a Role for Pharmacoeconomics in Developing Countries? Zaheer-Ud-Din Babar and Shane Scahill School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand The special issue of PharmacoEconomics [1] pertaining to developing nations was a welcome move, with authors discussing various themes relating to pharmaceutical economics. The topics discussed included cost-effectiveness analyses and the future of health technology assessment (HTA) in healthcare decision making in the greater Asia region. However, papers in this special issue did not provide an answer to a fundamental question: why is pharmacoeconomics vital for developing countries? Pharmacoeconomics is a complex science and its practical utility depends on the context in which it is being applied. To appreciate the true value of this science as a decision-making tool, it is important to elaborate on the context within which healthcare decisions are being made. Furthermore, an understanding of the local health system is also required in order to establish whether complex economic techniques need to be applied and whether they are feasible and valuable tools for a particular jurisdiction. We argue that there is a need for a model that could aid in determining the perceived need and benefits of using pharmacoeconomics in formulary development in a given developing country. However, we do not present a full model; rather, we highlight some of the components that could be used to build such a model. Health and pharmaceutical indicators from international agencies, evidence-based pharmacy-system research as well as the literature concerning how people perceive pharmacoeconomics in developing countries could serve as these components. 1. The Use and Understanding of Pharmacoeconomics in Developing Countries The application of pharmacoeconomics for comparing pharmacy services and treatment options is an accepted and valuable tool. [2] However, the utility of pharmacoeconomics for selecting drugs for national medicines formularies depends on various factors, including health system design and performance, the pharmaceutical situation [3] and the country s expenditure on pharmaceuticals (evaluating the pharmaceutical situation of a country requires pharmaceutical sector assessment, including whether people have access to safe, effective and affordable essential medicines of acceptable quality). We argue that it may not be necessary for many low-income countries to use complex costutility or cost-effectiveness techniques for selecting drugs for a national formulary. A medicine pricing policy could work as a first-line tool. In the recent issue of PharmacoEconomics, Yang [4] outlined the growth of pharmacoeconomics in Asia; however, he did not differentiate between countries (while discussing the utility of pharmacoeconomics), nor did he allude to any country-specific cost-effectiveness threshold. Although South Korea, Taiwan, the Philippines, Thailand and Malaysia are at different levels of health system development, Yang [4] did not take this into account and used a generic statement that, in all these countries pharmacoeconomics
2 2 Babar & Scahill has been or will be increasingly used. Although this may be the case in Taiwan and South Korea, for the Philippines, Malaysia and Thailand, the use of the simpler WHO medicines policy framework, [5] rational pricing policies and the use of generic medicines could be more appropriate as first-line strategies. The need for a careful approach in applying pharmacoeconomics has also recently been suggested by Oortwijn et al., [6] who noted that HTA is developing with uneven speed in middle-income countries. Based on the need to understand the context of individual health systems as they relate to the utility of pharmacoeconomics, we provide case study descriptions of three different country groupings. Criteria for the groupings are based on (a) the country s socioeconomic status; (b) recent pharmaceutical reforms; and (c) the advancement and maturity of health systems. 1.1 Group 1: South Korea and Taiwan BothSouthKoreaandTaiwanhavedeveloped regulatory structures regarding pharmaceuticals (table I). [12,13] In addition, pharmacy-system research is advancing and pharmaceutical reforms have recently taken place in these countries. [12,13] Pharmacy-system research encompasses research related to drug distribution, drug regulation, drug selection, procurement, pricing, generic medicines, and access and affordability of medicines. Pharmacysystem research can be integrated into healthsystem research and can be part of the national health policy of a country. [14] Some policy reforms have dealt with more complex issues, such as remuneration of pharmacists and the issue of dispensing separation; where the roles of pharmacists and doctors in prescribing are clearly differentiated. [12,13,15] The parameters on health system performance, income level, expenditure on pharmaceuticals and gross national income (see table I) indicate that both South Korea and Taiwan have relatively advanced pharmaceutical systems and may be ready to apply pharmacoeconomic models to help ensure rational medicine expenditures. That Taiwan has a Centre for Drug Evaluation (CDE) also supports the notion that this country has a relatively advanced pharmaceutical system. The CDE performs regulatory evaluations Table I. Socioeconomic and health indicators of developing countries and the utility of pharmacoeconomics for selecting drugs for reimbursement and essential medicines lists Country Gross national income ($US per capita) 2008 [7] Income level [8] Health system performance rank [8]a Health expenditure per capita ($US) 2007 [9] Total expenditure on pharmaceuticals (as % of total health expenditure) [8] Approximate utility of pharmacoeconomics Iran Medium Indonesia Low South Korea High Malaysia Medium Pakistan Low Philippines Low Saudi Arabia Medium Thailand Low-medium Taiwan (y 2005) [10] b b [11] High a Ranked out of 191 countries according to disability-adjusted life-expectancy. b Data for Taiwan are scarce, as Taiwan is not a member of many international agencies. 1 = low income level; 2 = middle income level; high = pharmaceutical systems are generally well established. Countries either have or are in the process of establishing economic evaluation authorities, using economic guidelines from developed countries. However, local health needs should be taken into account; low = pharmaceutical systems need restructuring and strengthening. The use of pharmacoeconomics could be low; medium = pharmaceutical systems and regulatory authorities are generally established, with few areas still needing improvement and strengthening. Pharmacoeconomics could be used in a few cases and for selected drugs.
3 Pharmacoeconomics in Developing Countries 3 of marketing application dossiers of new drugs and provides advice to the Taiwanese Department of Health. [6] Taiwan also explicitly evaluates evidence reports from the HTA agencies in the UK, Canada and Australia. [16] Furthermore, South Korea has a Health Insurance Review Agency (HIRA), which has developed pharmacoeconomic guidelines for pharmaceutical companies so that they can prepare economic data before submitting a drug application for reimbursement and pricing. [6] South Korea is also in the process of establishing a national agency along the lines of the UK National Institute for Health and Clinical Excellence (NICE). [17] However, Oortwijn et al. [6] have cautioned that establishing formal HTA agencies in middle-income countries is not the total solution and that complex local healthcare needs, service delivery arrangements and mechanisms available to implement guidance within the clinical community all need to be considered. 1.2 Group 2: Iran, Malaysia and Saudi Arabia According to the WHO, [8] the health systems in Saudi Arabia, Malaysia and Iran are considered satisfactory and established (albeit less than Group 1 see table I), although they still have some unresolved issues regarding access to medicines, affordability and medicine reimbursement. For example, in Malaysia, the prices of branded and generic drugs were found to be 16- and 6-fold higher than international reference prices (IRPs), respectively. [18] These median price ratios were derived from a standard methodology [19] developed by the WHO and Health Action International (HAI), which indicates whether prices are high or low in developing countries. If this ratio is <1 for public sector data (government hospitals, clinics, etc.) and <2 for private sector data (private pharmacies, medical stores), then the prices are considered reasonable. Iran has done well in promoting safe and effective use of medicines and has an effective medicines regulatory authority. [20-22] About 90% of the population has access to affordable medicines and a recent WHO/HAI study [23] suggested that government procurement medicine prices and patient prices for generic medicines were reasonable and that almost all surveyed medicines were affordable for workers on the minimum wage. Few originator brands are marketed; however, they are an average of 3- to 7-fold higher than the price of generic equivalents. Digoxin, metformin and carbamazepine were found to be 6- to 9-fold higher than the IRPs, indicating a need to reduce the prices of these medicines. These results clearly outline the need, particularly in Malaysia, for intervention. Iran, Malaysia and Saudi Arabia have all shown interest in pharmacoeconomics; [20,23-26] however, the data shown in table I and the evidence from WHO/HAI surveys [27] show that using HTA alone for all medicines as a blanket strategy will not solve the issue of cost containment. These countries could be potential candidates for applying mediumlevel use of pharmacoeconomics. By this we mean that countries could apply pharmacoeconomics to selected drugs (such as biotechnologies) together with other cost intervention strategies, including effective pricing policies. This argument is further supported by the lack of trained and experienced personnel to conduct, interpret and use HTA in developing countries, [6] and further strengthened by the way in which researchers perceive the term pharmacoeconomics. In Malaysia and Iran, a universally accepted definition of pharmacoeconomics is understood and used; [20,23,26] however, this is not the case for Saudi Arabia, where there is a relatively effective drug regulatory authority, [28] but there seems to be some discrepancy in understanding of the term pharmacoeconomics [25] (table II). Topics such as pharmaceutical system strengthening, pharmacoepidemiology, drug utilization and Ministry of Health Pricing Committee are covered by the pharmacoeconomics umbrella in Saudi Arabia. In Malaysia, pharmacoeconomics is not used to select drugs for inclusion on the essential drug lists; however, it is taught in undergraduate and post-graduate pharmacy programmes. [26] Iran has an acceptable level of pharmacy-system research, seems to have a good understanding of pharmacoeconomics and appears to use pharmacoeconomic principles in an appropriate fashion [20-23] (table II).
4 4 Babar & Scahill Table II. How do different countries perceive the term pharmacoeconomics? [20,21,25,29] Country Concepts regarding the term pharmacoeconomics Agreement of concepts with the standard definition of pharmacoeconomics a Pakistan Generation of local research data in priority areas Standard treatment guidelines and training Improving pharmacy and pharmacological education Development and strengthening of drug control organizations (district level) Need for evidence-based educational, managerial and regulatory interventions Low (discrepancies) Iran Saudi Arabia Health technology assessment Pricing New medicines Drug evaluation in hospitals Drug utilization review Ministry of Health Pricing Committee New guidelines for pharmacoeconomics and pricing High Medium (some discrepancies) a ISPOR defines pharmacoeconomics as the scientific discipline that evaluates the clinical, economic and humanistic aspects of pharmaceutical products, services, and programs, as well as other health care interventions to provide health care decision makers, providers and patients with valuable information for optimal outcomes and the allocation of health care resources. [30] ISPOR = International Society for Pharmacoeconomics and Outcome Research. 1.3 Group 3: Indonesia, Pakistan, Thailand and the Philippines Indonesia and Pakistan are considered lowincome countries [8] (United Nations [UN] income level 1), whilst Thailand and the Philippines are categorized as middle-income countries (UN level 2). [8] Health system performance in these four countries ranges from a rank of 99 to 124 of 191 countries, according to disability-adjusted life-expectancy (table I). These countries are less likely to benefit from applying pharmacoeconomic strategies than other countries, as their drug regulatory authorities need strengthening and other medicines policy interventions could more easily be employed in the initial stages. In Pakistan, a WHO/HAI pricing study [31] revealed that prices of branded drugs are an average of 2- and 3-fold higher than the IRP in the public and private sectors, respectively. As a result of non-availability of drugs at government hospitals, the people of Pakistan spend 77% of their healthcare budget buying medicines. [8] There are issues with availability, affordability and unethical medicine promotion. Understanding of the principles of pharmacoeconomics does not appear to be clear, with concepts such as standard treatment guidelines, and pharmacy and pharmacology education all referred to as pharmacoeconomics [29] (table II). Indonesia has similar problems: procurement prices paid by local government were 74% greater than IRPs for generic medicines. Patient prices were 2.4- and 2.8-fold greater than IRPs in the public and private sectors, respectively. [32] In Thailand, prices of public sector-procured generics were 1.46-fold higher than IRPs, while innovator brands were 3.3-fold higher. The prices patients pay in the private sector were and 3.31-fold higher than IRPs for branded and generic drugs, respectively. [33] The results of this study highlight priority areas for action and a requirement to improve the drug pricing policies. [33] In the Philippines, a survey in 2005 using WHO/HAI methodology [34] found that prices of originator brand medicines sold from private retail outlets were an average of 15-fold greater than the IRP, while the lowest-cost generic equivalents were more than 6-fold greater than the IRP. The situation in public facilities was similar, with reports of originator brands and lowest-priced generic medicines being procured at 14- and 5-fold the IRP, respectively. [34] Given this situation, it would be more rational for the Philippines to apply other pricing strategies before utilizing pharmacoeconomics. Thailand appears to have the expertise and capacity to understand and apply pharmacoeconomic techniques. [35] The Philippines and Thailand both have HTA programmes that help guide and apply pharmacoeconomics. [6] However, additional benefit
5 Pharmacoeconomics in Developing Countries 5 could be gained from strengthening pharmacy systems and applying pharmacoeconomics for selected drugs. Medicine prices are very high in Thailand and the Philippines, and pricing-intervention strategies could improve the access to and affordability of medicines. In this context, Thailand also seems to be on the higher economic scale in this group and is in a better position to apply low- to mediumlevel use of pharmacoeconomics. 2. Moving Forward We argue that the use of pharmacoeconomic theory and modelling should not be hyped-up but should be realistic according to a country s health status, academic capacity and pharmaceutical situation. We demonstrate that, in many cases, the country s socioeconomic and health indicator status matches performance in the pharmaceutical sector. This provides some support for integrating these socioeconomic components into a model for determining the utility of pharmacoeconomics that could be titled the approximate-utility model of pharmacoeconomics. Further work is required in this area and the aim of this article is to create debate and provide a platform for discussion and continued dialogue. Acknowledgements No sources of funding were used to prepare this article. The authors have no conflicts of interest that are directly relevant to the content of this article. References 1. Singer ME. Developing nations special issue. Pharmacoeconomics 2009; 27 (11): Babigumira JB, Sethi AK, Smyth KA, et al. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 2009; 27 (11): WHO. WHO operational package for assessing, monitoring and evaluating country pharmaceutical situations: guide for coordinators and data collectors [WHO/TCM/2007.2]. Geneva: WHO, 2007 Dec [online]. Available from URL: 877e.pdf [Accessed 2010 Aug 29] 4. Yang B-M. The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics 2009; 27 (11): How to develop and implement a national drug policy. 2nd ed. Geneva: WHO, 2001 [online]. Available from URL: [Accessed 2010 Aug 28] 6. Oortwijn W, Mathijssen J, Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy 2010; 95: The World Bank. GNI per capita, Atlas method (current US$) [online]. Available from URL: bank.org/indicator/ny.gnp.pcap.cd [Accessed 2010 Aug 26] 8. WHO. The world medicines situation [WHO/EDM/PAR/ ]. Geneva: WHO, 2004 [online]. Available from URL: Medicines_Situation.pdf [Accessed 2010 Aug 19] 9. The World Bank. Health expenditure per capita (current US$) [online]. Available from URL: org/indicator/sh.xpd.pcap [Accessed 2010 Aug 22] 10. Taiwan: Hutchinson country facts [online]. Available from URL: countryfacts/taiwan.html [Accessed 2010 Jul 7] 11. Leung GM, Wagstaff A, Lindelow M, et al. The health systems of China, Hong Kong and Taiwan. In: Heggenhougen K, Quah S, editors. International encyclopedia of public health. San Diego (CA): Academic Press, 2008: Kima HJ, Chungb W, Lee SG. Lessons from Korea s pharmaceutical policy reform: the separation of medical institutions and pharmacies for outpatient care. Health Policy 2004 June; 68 (3): Chou YJ, Yip WC, Lee CH, et al. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan s experience. Health Policy Plann 2003; 18 (3): Laing R. Health and pharmacy systems in developing countries Apr 9 [online]. Available from URL: wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/ 05laing_e.pdf [Accessed 2001 Apr 9] 15. Kwon S. Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing. Soc Sci Med 2003 Aug; 57 (3): Tarn TY-H. Case of Taiwan HTA. Presentation at the 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; Seoul 17. Kim C. Health technology assessment in South Korea. Int J Technol Assess Health Care 2009; 25 (Suppl. 1): Babar ZU, Ibrahim M, Izham M, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 2007; 4 (3): WHO, Health Action International. Medicine prices: a new approach to measurement ed. [working draft for field testing and revision]. Geneva: WHO, 2003 [online]. Available from URL: EDM_PAR_ pdf [Accessed 2010 Aug 28] 20. Cheraghali AM. Pharmacoeconomics: an effective tool for prioritization in Iran healthcare system. Iranian J Pharmaceutical Res 2008; 7 (2): [online]. Available from URL: [Accessed 2010 Aug 27] 21. Dinarvand R. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of
6 6 Babar & Scahill public to medicines. Iranian J Publ Health 2009; 38 Suppl. 1: [online]. Available from URL: ac.ir/upload_files/pdf/13390.pdf [Accessed 2010 Aug 29] 22. Cheraghali AM. Iran pharmaceutical market. Iranian J Pharmaceutical Res 2006; 1: 1-7 [online]. Available from URL: [Accessed 2010 Aug 29 ] 23. Iranian National Society of PharmEconomics [online]. Available from URL: [Accessed 2010 Jul 29] 24. Iran, medicine prices, affordability and availability. Amsterdam: Health Action International, (Data on file) 25. Sultan MSA. How to integrate pharmacoeconomic data in the Middle East countries: the status in Saudi Arabia. Pharmacoeconomics Meeting, Servier International; 2008 Jan 24; Cairo 26. University Sains Malaysia. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Pharmacoeconomics, Undergraduate course. Penang [online]. Available from URL: dergrad.asp [Accessed 2010 Aug 24] 27. Health Action International. Medicine prices, availability, affordability and price components [online]. Available from URL: results.php [Accessed 2010 Aug 29] 28. Kingdom of Saudi Arabia. Saudi Food and Drug Authority [online]. Available from URL: Drug/Topics/Human_Drugs.htm [Accessed 2010 Aug 23] 29. Hameed A. Pharmacoeconomics and outcome research in Pakistan [online]. Available from URL: org/conferences/shanghai0306/pdf/07-pakistan-hameed.pdf [Accessed 2010 Aug 20] 30. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Brief definition [online]. Available from URL: [Accessed 2010 Sep 20] 31. The Network for Consumer Protection. Prices, availability and affordability of medicines in Pakistan. Islamabad: The Network for Consumer Protection, 2006 [online]. Available from URL: PK/survey_report.pdf [Accessed 2010 Aug 19] 32. WHO, Health Action International. Indonesia: medicine prices, availability and affordability [online]. Available from URL: ID/sdocs/Indonesia-summary-report-FINAL.pdf [Accessed 2010 Jul 23] 33. Sooksriwong C, Yoongthong W, Suwattanapreeda S, et al. Medicine prices in Thailand: a result of no medicine pricing policy. Southern Med Review 2009; 2 (2): [online]. Available from URL: index/assoc/s16381e/s16381e.pdf [Accessed 2010 Jul 27] 34. WHO, Health Action International. Philippines: public procurement prices of medicines [online]. Available from URL: PHB/sdocs/zPhilippines-procurement-Final.pdf [Accessed 2010 Aug 22] 35. International Health Economics Association (ihea). Chulalongkorn University: introduction to pharmacoeconomics [online]. Available from URL: nomics.org/education/2004/06/chulalongkorn-universityintroducti.html [Accessed 2010 Aug 26] Correspondence: Dr Zaheer-Ud-Din Babar, School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Mail Bag 92019, Auckland 1142, New Zealand. z.babar@auckland.ac.nz
Access to affordable essential medicines 1
35 Access to affordable essential medicines 1 Target 8e In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries. Target 8e of the Millennium Development
More informationSPEAKER BIOGRAPHICAL INFORMATION
SPEAKER BIOGRAPHICAL INFORMATION Madeleine R. Valera MD, MScIH (Heidelberg) Dr. Valera is a senior health care service professional with over 20 years of professional expertise in Health Financing and
More informationComparisons of Health Expenditure in 3 Pacific Island Countries using National Health Accounts
Comparisons of Health Expenditure in 3 Pacific Island Countries using National Health Accounts Hopkins Sandra* Irava Wayne. ** Kei Tin Yiu*** *Dr Sandra Hopkins PhD Director, Centre for International Health,
More informationEvidence-based Health Policies for Medical Devices and Diagnostics in Asia. Outline of Presentation
Evidence-based Health Policies for Medical Devices and Diagnostics in Asia Prof Phua Kai Hong Chair, 2007-2008 Asia-Pacific Medical Devices & Diagnostics Council Lee Kuan Yew School of Public Policy The
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More informationS P E C I A L I S T A N D M A S T E R S T U D I E S
University Ss, Cyril and Methodius Skopje FACULTY OF PHARMACY S P E C I A L I S T A N D M A S T E R S T U D I E S Healthcare management and pharmacoeconomics Skopje, 2007 STUDY PLAN -Specialist Studies-
More informationGovernance, Risk and Compliance Assessment
Governance, Risk and Compliance Assessment Information security is a pervasive business requirement and one that no organisation can afford to get wrong. If it s not handled properly, your business could
More informationHealth Care Services
Abdulaziz H Al Saggabi, BSc, MSc, PharmD, Director, Drug Policy & Economics Center National Guard Health Affair & President ISPOR Saudi Arabia Chapter Presentation Outline y Background of Saudi Arabia
More informationEvidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwanvhe_620 4..
Volume 12 Supplement 3 2009 VALUE IN HEALTH Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwanvhe_620 4..11 Thidaporn Jirawattanapisal,
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationThe Evolution of Taiwan National Health Insurance Drug Policy - Review and Analysis
The Evolution of Taiwan National Health Insurance Drug Policy - Review and Analysis Chih-Sheng (Jason) Hsu ICIUM Antalya, Turkey / Nov. 14-18, 2011 Introduction Types of Social Insurance Intervention Category
More informationInternational Regulatory Cooperation for Herbal Medicines (IRCH)
International Regulatory Cooperation for Herbal Medicines (IRCH) Presentation to ICDRA Members 30 November 2010 YEE Shen Kuan Senior Advisor, Health Products Regulation Group Health Sciences Authority,
More informationGroup sales 10% Weak SEA currencies accounted for ~3% decrease Global brand sales 4% from improvements in China franchisee performance
2016 First Quarter Update 4 May 2016 Overview Group sales 1 Weak SEA currencies accounted for ~3% decrease Global brand sales 4% from improvements in China franchisee performance Gross margin 2.5pp; gross
More informationBank of America Merrill Lynch Banking & Financial Services Conference
Bank of America Merrill Lynch Banking & Financial Services Conference Manuel Medina Mora Chairman of the Global Consumer Banking Council November 17, 2010 Consumer Banking in Citicorp Agenda Our Business
More informationOctober 2013 - Bottled Water Exports and Imports continue to grow!
October 13 - Bottled Water Exports and Imports continue to grow! Annualised exports for the year to October 13 continue an upwards climb following their break through NZD1m last month. Leading markets
More informationChallenges for Capital Market Development in Asia
Challenges for Capital Market Development in Asia Osaka, 30 October 2014 Masamichi Kono Vice Minister for International Affairs President, Asian Financial Partnership Center Financial Services Agency,
More informationPharmaceutical Policy in Korea: Role of Health Insurance in Pricing, Reimbursement and Monitoring
Pharmaceutical Policy in : Role of Health Insurance in Pricing, Reimbursement and Monitoring Soonman KWON* and Sukyeong KIM** *Dean, School of Public Health Seoul National University ** Director, Research
More informationMedIC 2007: Facilitator List (alphabetical by last name)
MedIC 2007: Facilitator List (alphabetical by last name) Dr. John Chalker Management Sciences for Health Center for Pharmaceutical Management 4301 North Fairfax Drive, Suite 400 Arlington, VA 22203 USA
More informationJesse Brown VA Medical Center 820 South Damen Ave. Chicago Illinois 60612
Jesse Brown VA Medical Center is a tertiary care facility classified as a Clinical Referral Level II Facility. It is a teaching hospital, providing a full range of patient care services, with state-ofthe-art
More informationDividends Tax: Summary of withholding tax rates per South African Double Taxation Agreements currently in force Version: 2 Updated: 2012-05-22
Dividends Tax: Summary of withholding tax rates per South African Double Taxation Agreements currently in force Version: 2 Updated: 2012-05-22 Note: A summary of the rates and the relevant provisions relating
More informationTo Be A Leader and A Premier Educational Hub in the Promotion of Afforable and Quality E-Learning in Asia
Executive Bachelor of Business (General Management) To Be A Leader and A Premier Educational Hub in the Promotion of Afforable and Quality E-Learning in Asia THE 1 UNIVERSITY 1 st ASIAN 31 COUNTRIES MULTINATIONAL
More informationThe Impact of Medicare Part D on the Percent Gross Margin Earned by Texas Independent Pharmacies for Dual Eligible Beneficiary Claims
The Impact of Medicare Part D on the Percent Gross Margin Earned by Texas Independent Pharmacies for Dual Eligible Beneficiary Claims Angela Winegar, M.S., Marvin Shepherd, Ph.D., Ken Lawson, Ph.D., and
More informationMERCER WEBCAST CHARTING YOUR COURSE FOR GLOBAL EXPANSION MANAGING EXPATRIATE MEDICAL PLANS
MERCER WEBCAST CHARTING YOUR COURSE FOR GLOBAL EXPANSION MANAGING EXPATRIATE MEDICAL PLANS APRIL 10, 2014 Joe Barber, New York Mark Harris, London Today s Speakers MERCER Joe Barber New York Mark Harris
More informationAn Overview of Offshore RMB Market. Nov 2013
An Overview of Offshore RMB Market Nov 2013 Contents 1. Outlook of RMB Internationalisation 2. Implications for Offshore RMB Bonds 2 Section 1 Outlook of RMB Internationalisation 3 RMB The next international
More informationMedicines Benefits in Korea
Medicines Benefits in Korea International Expert Meeting on Medicines as a Key Component of Universal Health Coverage Singapore - Oct 2, 2013 Soonman KWON, Ph.D. Dean School of Public Health Seoul National
More informationHow To Get A New Phone System For Your Business
Cisco Phone Systems Telemarketing Script Cold Call 1. Locate Contact: Name listed Owner General Manager / Office Manager Chief BDM (Business Decision Maker) Note: Avoid talking to IT since this is not
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More information3. Financing. 3.1 Section summary. 3.2 Health expenditure
3. Financing 3.1 Section summary Malaysia s public health system is financed mainly through general revenue and taxation collected by the federal government, while the private sector is funded through
More informationContinuing education for community pharmacists in Denmark the case of Master of Drug Management
Continuing education for community pharmacists in Denmark the case of Master of Drug Management Birthe Søndergaard Associate Professor Department of Pharmacology and Pharmacotherapy, Section of Social
More informationUNIVERSITI SCIENCE MALAYSIA (USM) 2012-2013 SPONSORED BY: UNIVERSITY SAINS MALAYSIA THE COLOMBO PLAN
MASTER OF PUBLIC ADMINISTRATION (MPA) MASTER OF SOCIAL WORK (MSW) MASTER OF ECONOMIC MANAGEMENT (MEM) MASTER OF SOCIAL SCIENCE (ASIAN STUDIES) MASTER OF SOCIAL SCIENCE (ISLAMIC DEVELOPMENT MANAGEMENT)
More informationWest Virginia University School of Pharmacy Educational Outcomes Professional Curriculum Approved by the Faculty: October 11, 2013
West Virginia University School of Pharmacy Educational Outcomes Professional Curriculum Approved by the Faculty: October 11, 2013 1 Preamble The School of Pharmacy s educational outcomes (EOs) are designed
More informationThe College of Family Physicians of Canada. Position Statement Prescribing Rights for Health Professionals
The College of Family Physicians of Canada Position Statement Prescribing Rights for Health Professionals Introduction The College of Family Physicians of Canada (CFPC) supports models of practice that
More informationAbdul Zahir Siddiqui, 1 Fahima Habibi, 2, Noorulhaq Yousufzai, 3 Lutfullah Ehsaas, 1 M. Zafar Omari, 1 Niranjan Konduri, 4 Terry Green 4
Pharmaceutical Management Interventions Through a Drug and Therapeutics Committee (DTC) in Kabul, Afghanistan: Initial Experience After Decades of Neglect Abdul Zahir Siddiqui, 1 Fahima Habibi, 2, Noorulhaq
More informationJMA Consultants Inc. Corporate Introduction
JMA Consultants Inc. Corporate Introduction Self Introduction Publications Cost half promoting manual (Collective writing), JMAM,1995. Introduction to MOT Management (Collective writing ), PHP, 2004 The
More informationHealth Insurance Systems in Five Sub-Saharan African Countries: Medicines Benefits and Data for Decision-Making
Health Insurance Systems in Five Sub-Saharan African Countries: Medicines Benefits and Data for Decision-Making Carapinha, Joao (1); Ross-Degnan, Dennis (2); Tamer Desta, Abayneh (3); Wagner, Anita (2)
More information5. 16. Health Law in Canada. Constitutional Division of Power
Health Law in Canada Health care in Canada is a complex subject, some health care services are public, some are private and there are a number of different entities involved in regulating and providing
More informationPOSIAH MOHD ISA EDUCATION MALAYSIA EMBASSY OF MALAYSIA
POSIAH MOHD ISA EDUCATION MALAYSIA EMBASSY OF MALAYSIA Malaysia is one of the Newly Industrialized Countries in Asia. By the year 2020 : fully industrialized The expansion of the economy in 80 s & 90 s
More informationAugust 2011. A. Introduction
Recommendations of the Expert Group on the Regulatory Framework for products containing buprenorphine / naloxone and buprenorphine-only for the treatment of opioid dependence August 2011 A. Introduction
More informationAnalysis of Hospital Pharmaceuticals
Danish Ministry of Health and Prevention Analysis of Hospital Pharmaceuticals Country Report - Germany March 2009 COWI A/S Parallelvej 2 DK-2800 Kongens Lyngby Denmark Tel +45 45 97 22 11 Fax +45 45 97
More informationFlexible Cloud Services to Compete
white paper Service Providers Need Flexible Cloud Services to Compete Enterprise Customers Demand Flexible Cloud Solutions When the concept of cloud services first came about, there was a great deal of
More informationMedical Tourism Malaysia. Tan Sri Dato Dr Abu Bakar Suleiman President International Medical University (IMU), Kuala Lumpur, Malaysia
Medical Tourism Malaysia Tan Sri Dato Dr Abu Bakar Suleiman President International Medical University (IMU), Kuala Lumpur, Malaysia Medical Tourism - Malaysia Development of Medical Tourism Malaysia Medical
More informationGroup Companies and Network
Annual Report 2009 By business segment as of March 31, 2009 Operations in Japan Corporate Financial Services Domestic Sales Administrative Headquarters Lending, Leasing, Other Financial Services Apr. 1964
More informationJoint General Assembly APLAC-PAC 2014 June 21-28, Guadalaja, Mexico
Joint General Assembly APLAC-PAC 2014 June 21-28, Guadalaja, Mexico Suggestions air transportation to Guadalajara, Mexico Below are some suggested connections that can be taken from different countries
More informationOverview of Asian Insurance Markets
Overview of Asian Insurance Markets Simon Walpole Session Number: TPS2 Joint IACA, IAAHS and PBSS Colloquium in Hong Kong www.actuaries.org/hongkong2012/ Market Ranking in Asia Notes: 1. Colored boxes
More informationTo Be A Leader and A Premier Educational Hub in the Promotion of Afforable and Quality E-Learning in Asia
Executive Master of Business ( General Management ) To Be A Leader and A Premier Educational Hub in the Promotion of Afforable and Quality E-Learning in Asia THE 1 UNIVERSITY 1 st ASIAN 33 COUNTRIES MULTINATIONAL
More informationOPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS
OPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS April 27 29, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL MEETING OF ISMPP 1 ORGANIZED HEALTHCARE
More informationTUITION AND OTHER FEES
TUITION AND OTHER FEES RESEARCH MODE (MASTER AND PHD) PURE ARTS Humanities, Social, Language & Translation Distance Education (Arts), Archeology APPLIED SCIENCES Drug Research, Doping Control Centre, National
More informationLEVERAGING PHILIPPINE HUMAN RESOURCES FOR NATIONAL DEVELOPMENT AND INTERNATIONAL COMPETITIVENESS
LEVERAGING PHILIPPINE HUMAN RESOURCES FOR NATIONAL DEVELOPMENT AND INTERNATIONAL COMPETITIVENESS QUALITY ASSURANCE AND PHILIPPINE HIGHER EDUCATION REFORM 11 FEBRUARY 2014 PRESENTATION OUTLINE THE CONTEXT:
More informationDual-Use Bioethics / Biosecurity Online Learning Train-the-Trainer Program
Dual-Use Bioethics / Biosecurity Online Learning Train-the-Trainer Program Simon Whitby 31st Workshop of the Pugwash Study Group on the Implementation of the Chemical and Biological Weapons Conventions:
More informationDisaster Recovery and Online Backup as a Service
Disaster Recovery and Online Backup as a Service Global Overview & Outlook AMI-Partners 546 Fifth Avenue, New York, NY 10036 212-944-5100 www.ami-partners.com Source: AMI-Partners (www.ami-partners.com)
More informationANNEX TABLES Table 1. Revenue by ICT Type Revenue * Share to Total Revenues Growth Rate ICT Type 2004 2005 2004 2005 (in percent)
ANNEX TABLES Table 1. Revenue by Revenue * Share to Revenues 2004 2005 2004 2005 Contact Centers 32,904.1 54,295.1 44.4 49.4 65.0 Medical Transcription 236.7 466.2 0.3 0.4 97.0 Animation 694.2 939.1 0.9
More informationAAPBS. Association of Asia-Pacific Business Schools. www.aapbs.org
AAPBS Association of Asia-Pacific Business Schools www.aapbs.org Welcome to the world of Asia-Pacific business education MESSAGE FROM THE PRESIDENT To our Academic, and Executive colleagues: Globalization
More informationInvesco Funds Series 1-5 Consolidated Prospectus
Invesco Funds Series 1-5 Consolidated Prospectus 26 November 2010 Invesco Funds Series 1 Invesco Funds Series 2 Invesco Funds Series 3 Invesco Funds Series 4 Invesco Funds Series 5 Each an open-ended umbrella
More informationCommunity Pharmacy in 2016/17 and beyond - proposals Stakeholder briefing sessions
Community Pharmacy in 2016/17 and beyond - proposals Stakeholder briefing sessions 1 CONTENTS Contents This presentation describes our vision for community pharmacy, and outlines proposals for achieving
More informationHow To Get Involved In An Australian Business School
Association of Asia-Pacific Business School 2015 www.aapbs.org MESSAGE FROM THE PRESIDENT Members, friends and colleagues Is humility and caring unrelated to costs and cash flows? Is peace unrelated to
More informationHealth Care Reform: The Question of Essential Benefits. The third report in Mercer s ongoing series of topical surveys on health reform
Health Care Reform: The Question of Essential Benefits The third report in Mercer s ongoing series of topical surveys on health reform Why a survey on essential benefits? Essential health benefits make
More informationSoftware-as-a-service Delivery: The Build vs. Buy Decision
white paper Software-as-a-service Delivery: The Build vs. Buy Decision Introduction In order to deliver software on-demand, companies must either build and manage an infrastructure capable of supporting
More informationObjectives. P&T Committee. P&T Committee Structure. Utilization of P&T Committees
Objectives Discuss overview of forum purpose. Drug Information used in the Managed Care Pharmacy P&T Decision Making Process: Current Practice and Insights Diana Brixner, RPh, PhD Professor and Chair,
More informationHealth Care in the Global Market. Bill Atwell President, CIGNA International
Health Care in the Global Market Bill Atwell President, CIGNA International Health Care in the Global Market Agenda A CIGNA International overview Current global health care environment Our business strategy
More informationThe role, responsibilities and status of the clinical medical physicist in AFOMP
Australasian Physical & Engineering Sciences in Medicine Volume 32 Number 4, 2009 AFOMP POLICY STATEMENT N O 1 The role, responsibilities and status of the clinical medical physicist in AFOMP K. H. Ng*
More informationHKCS RESPONSE COMMONLY ACCEPTED AUDIT OR ASSESSMENT MECHANISM TO CERTIFY INFORMATION SECURITY STANDARDS
Hong Kong Computer Society Room 1915, 19/F, China Merchants Tower, Shun Tak Centre, 168 Connaught Road Central, Hong Kong Tel: 2834 2228 Fax: 2834 3003 URL: http://www.hkcs.org.hk Email: hkcs@hkcs.org.hk
More informationIntroduction of a Standard Drug Formulary in Hospital Authority
Introduction of a Standard Drug Formulary in Hospital Authority PURPOSE This paper seeks Members views on the introduction of a Standard Hospital Authority Drug Formulary ( ) ( Standard Drug Formulary
More informationWorld Consumer Income and Expenditure Patterns
World Consumer Income and Expenditure Patterns 2014 14th edi tion Euromonitor International Ltd. 60-61 Britton Street, EC1M 5UX TableTypeID: 30010; ITtableID: 22914 Income Algeria Income Algeria Income
More informationHealth Technology Assessment in selected Countries
Health Policy 95 (2010) 174 184 Contents lists available at ScienceDirect Health Policy journal homepage: www.elsevier.com/locate/healthpol The role of health technology assessment on reimbursement in
More informationOpen Doors 2011 Report on International Educational Exchange
Open Doors 2011 Report on International Educational Exchange Produced by the Institute of International Education with support from the Bureau of Educational and Cultural Affairs of the U.S. Department
More informationStudent visa and Temporary Graduate visa programme quarterly report
Student visa and Temporary Graduate visa programme quarterly report quarter ending at 30 June 2015 This page is left blank intentionally. Table of Contents Page About this report 1 Enquiries 1 Definition
More informationThe Socio-economic Environment of Greece
HTA DEVELOPMENTS IN THE CENTRAL AND EASTERN EUROPEAN REGION: LOCK, STOCK & BARREL IN CHALLENGING TIMES The experience of GREECE Mary Geitona, MSc, Ph.D President ISPOR Greece Chapter As. Professor, University
More informationThe Impact of Multilateral Agreements on Future Health Workforce Supply and Governance? Australia and ASEAN Region
The Impact of Multilateral Agreements on Future Health Workforce Supply and Governance? Australia and ASEAN Region Lesleyanne Hawthorne Professor International Health Workforce 15 th International Health
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. Asia-Pacific Insurance Industry 1.1. Industry Introduction 1.2. Asia-Pacific Insurance Market Size by Direct Written Premium, 2005-2012P 1.3. Asia-Pacific Insurance Market Segmentation
More informationDoctoral Nursing Education in South Korea
Doctoral Nursing Education in South Korea Hyeoun-Ae Park, RN, PhD, FAAN*, Ok Soo Kim, RN, PhD**, Myung Kyung Lee, RN, PhD*** Introduction History of nursing education in Korea goes back to 1903 when Bogu
More informationNatalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
More informationACC San Diego Chapter
ACC San Diego Chapter Biomedical and Technology Collaborations with Chinese Companies: Legal and Cultural Challenges October 2012 DLA Piper Overview Our Firm 4,200 lawyers in 77 offices and 33 countries
More informationBrain Drain and Brain Gain: Selected Country Experiences and Responses
Brain Drain and Brain Gain: Selected Country Experiences and Responses Manuel M. Dayrit MD, MSc Dean, Ateneo School of Medicine and Public Health Manila, Philippines manuel_m_dayrit@yahoo.com Australia,
More informationSession 4: The Drug Management Cycle: Selection. David Peters
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationDegree Recognition & its Impact on Student Mobility
Degree Recognition & its Impact on Student Mobility Mariam Assefa Executive Director World Education Services DAAD Seminar NAFSA 2009 INTERNATIONAL EDUCATION INTELLIGENCE Content The context The environment
More informationDisinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review Bonny Parkinson, Catherine Sermet, Fiona Clement, Steffan Crausaz, Brian Godman, Sarah Garner, Moni Choudhury,
More informationAIA Singapore Company Factsheet
AIA Company Factsheet Becoming s pre-eminent life insurer March 2016 aia.com.sg AIA GROUP REAL FACTS Touching lives in 18 MARKETS across Asia-Pacific China 1919 Hong Kong 1931 1931 Thailand 1938 Philippines
More informationHow To Promote Healthcare Management
Welcome! Global Healthcare Management Consortium Under the auspice of With the leadership and support of The science of medicine is thousands of years old. The discipline of management sciences which includes
More informationSTATE OF GLOBAL E-COMMERCE REPORT (Preview) February 2013
STATE OF GLOBAL E-COMMERCE REPORT (Preview) February 2013 THE E-COMMERCE REPORT WHAT IS THE E-COMMERCE REPORT? It is an annual investigation into the global uptake and impact of e- commerce. The report
More information2013 Report on Costs of Treatment in the President s Emergency Plan for AIDS Relief (PEPFAR)
2013 Report on Costs of Treatment in the President s Emergency Plan for AIDS Relief (PEPFAR) Background The rapid expansion of access to antiretroviral treatment (ART) under PEPFAR has been one of the
More informationUKCPA - A Review of the Current Pharmaceutical Facility
Modernising Pharmacy Careers Review of Post-Registration Career Development Discussion Paper PRO FORMA FOR CAPTURING RESPONSES TO STAKEHOLDER QUESTIONS Please complete and return to: MPCProgramme@dh.gsi.gov.uk
More informationCreating an international pharmacy-led healthcare group
3 October 2005 Alliance Boots plc 1 Legal disclaimer This presentation does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any security, nor shall there be any
More informationCarnegie Mellon University Office of International Education Admissions Statistics for Summer and Fall 2010
Carnegie Mellon University Admissions Statistics for and Fall 2010 New International Students and Fall 2010 Undergraduate 208 16.1% Master's 799 61.7% Doctorate 177 13.7% Exchange 80 6.2% 31 2.4% Total
More informationSecurity Assessment and Compliance Services
Security Assessment and Compliance Services Despite the best efforts of IT security teams, hackers and malicious code continue to find their way into corporate networks. Adding to the pressure is the fact
More informationIt looks like your regular telephone.
It looks like your regular telephone. But it s a lot better. CISCO PHONE SYSTEM SOLUTIONS FOR SMALL AND MEDIUM BUSINESSES Between the increased productivity and administrative savings we ve experienced,
More informationThe Burden of the Complicated Type 2 Diabetes Patient in China. White Paper
White Paper Catalysts driving successful decisions in life sciences. The Burden of the Complicated Type 2 Diabetes Patient in China by Marco DiBonaventura, Ph.D. Director, Health Economics and Outcomes
More informationThe University of Hong Kong. Master of Sports Administration (2008 / 2009) (Course No. HS 29-818-00/81) Subject to Approval
The University of Hong Kong Master of Sports Administration (2008 / 2009) (Course No. HS 29-818-00/81) Subject to Approval Master of Sports Administration HS 29-818-00/81 The Master of Sports Administration
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationTackling runaway drug plan costs
Tackling runaway drug plan costs Drug management solutions not as tough a pill for employees to swallow Another Bright Paper brought to you by Sun Life Financial Group Benefits. September 2011 Foreword
More informationPharmacoeconomics and outcomes research degree-granting PhD programs in the United States
Research in Social and Administrative Pharmacy 9 (2013) 108 113 Research Briefs Pharmacoeconomics and outcomes research degree-granting PhD programs in the United States Julia F. Slejko, Ph.D.*, Anne M.
More informationMINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY
MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY Academic Reference Standards of Pharm.-D Program College of Pharmacy-University of Hail May The Major shift in the health-care system
More informationGlobal Student Mobility 2025 Forecasts of the Global Demand for Pathways to Higher Education in the Schools, VET and ELICOS sectors
Global Student Mobility 2025 Forecasts of the Global Demand for Pathways to Higher Education in the Schools, VET and ELICOS sectors Andrew Hewett IDP Education Australia Agenda and Key Issues Pathways
More informationStudent visa and Temporary Graduate visa programme quarterly report
2010-11 Student visa and Temporary Graduate visa programme quarterly report Quarter ending at 31 December 2014 Contents Page About this report 1 Enquiries 1 Definition of terms 2 Background to the student
More informationQuality in Healthcare The contribution of accreditation. Triona Fortune Berne 26 April 2013
Quality in Healthcare The contribution of accreditation Triona Fortune Berne 26 April 2013 Overview External Evaluation What are the benefit's? How can we make it better? Language 2 Why the demand? External
More informationIntroduction of Nanyang Business School PhD Program & Scholarship Information
Introduction of Nanyang Business School PhD Program & Scholarship Information Nanyang Business School MISSION To educate global business leaders and to advance knowledge in the theory and practice of management
More informationCurriculum Vitae. 2. Contacts 2.1 Email mahbeik@yahoo.com, mahbeik@gmail.com. 3. Education and Training
Curriculum Vitae 1. General Information Surname: Samadbeik Forename: Mahnaz Title: PhD in Health Information Management Rank: Assistant Professor Sex: Female Place of birth: 2. Contacts 2.1 Email mahbeik@yahoo.com,
More informationMedicine price regulation the South African experience
Medicine price regulation the South African experience Dr Anban Pillay Chief Director: Health Financing and Economics National Department of Health PillaA@health.gov.za pillayanban@yahoo.com.au Tel: +27
More informationWorking Holiday Maker visa programme report. 31 December 2014
Working Holiday Maker visa programme report 31 December 2014 Contents Page About this report 1 Enquiries 1 Definition of terms 2 Background to the Working Holiday Maker programme 3 Recent developments
More informationHow Transparent are Regulatory Agencies with regard to Review Timelines? Disclaimer
How Transparent are Regulatory Agencies with regard to Review Timelines? A Global Review Rosanna Melchior Sr Manager, Reg.Intelligence THOMSON REUTERS, France Disclaimer The views and opinions expressed
More information